Paper - WANFANG MED ONLINE

You Position: Home > Paper

Effect of DMSO concentrations on cryopreservation of suckling porcine hepatocytes

( views:210, downloads:1 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 12

DOI:: 10.3969/j.issn.1009-3079.2002.12.008

Key Word:: No keyword available

Abstract：目的:探索适宜于乳猪肝细胞-80℃长期低温保存的冻存保护剂浓度.方法:体外分离乳猪肝细胞,以含不同浓度二甲基亚砜(DMSO,浓度分别为50、100、150和200mL/L)的低温保存液-80C分别保存肝细胞30 d与60 d.复苏后接种培养,对其存活率、贴壁率、白蛋白及尿素合成能力等进行检测,并观察其形态结构变化.结果:不同DMSO浓度的低温保存液保存复苏后猪肝细胞的活力及形态学表现均有所不同,其中含50 mL/L DMSO低温保存液组保存效果最差;100mL/L组次之;150 mL/L组最佳.150 mL/L DMSO低温保存液组保存60 d肝细胞复苏后的存活率为81%,贴壁率是79%,较mL/L与100mL/LDMSO组有显著性差别(P＜0.05),150 mL/l DMSO组复苏后接种培养肝细胞的形态与未冻存组无明显差别,均保持较强的合成尿素及白蛋白能力.结论:150 mL/L DMSO浓度适合于乳猪肝细胞的-80℃长期超低温保存,保存时间对其活力无明显影响.冷冻保存;冻存保护剂;二甲基亚砜.

Reference

[1]陈钟,丁义涛,张鹤云.无血清培养基培养乳猪肝细胞的效果[J].2002,(3).
[2]陈钟,丁义涛,张鹤云.乳猪肝细胞的低温保存[J].2002,(2).
[3]刘俊,王英杰,王宇明,等.分离人肝细胞的超低温保存[J].2001,(4).
[4]周晓东,刘丽.人工肝脏体外支持系统的成年猪肝细胞分离和培养[J].2001,(9).
[5]WANG Ying-jie,LI Meng-dong,WANG Yu-ming,etc.Experimental study of bioartificial liver with cultured human liver cells[J].1999,(2).
[6]张颖,白雪帆,黄长形,等.肝细胞体外培养技术的研究现状[J].2002,(3).
[7]王英杰,刘国栋,刘俊,等.大量分离乳猪肝细胞的方法[J].1999,(8).
[8]李俊刚,陈耀凯.生物人工肝细胞材料研究进展[J].2002,(6).
[9]Ying Jie Wang,Meng Dong Li,Yu Ming Wang,etc.Effect of extracorporeal bioartificial liver support system on fulminant hepatic failure rabbits[J].2000,(2).
[10]Yun-Qing Yao,Ding-Feng Zhang,Ai-Long Huang,etc.Effects of electroporation on primary rat hepatocytes in vitro[J].2002,(5).
[11]Becquemont L,Sarkis R,Capeau J,etc.Survival and differentiation of porcine hepatocytes encapsulated by semiautomatic device and allotransplanted in large number without immunosuppression.[J].2001,35(2).
[12]Unger JK,Horn NA,Rossaint R,etc.Comparative analysis of metabolism of medium- and plasma perfused primary pig hepatocytes cultured around a 3-D membrane network.[J].2000,23(2).
[13]Horvat M,Sheil AG,Woodman K,etc.Cryopreserved porcine hepatocytes in a liver biodialysis system.[J].2001,33(1).
[14]Muraca M,Carraro P,Vilei MT,etc.Comparison of pig, human and rat hepatocytes as a source of liver specific metabolic functions in culture systems--implications for use in bioartificial liver devices.[J].2001,24(6).
[15]Enosawa S,Matsumura T,Omasa T,etc.In vivo estimation of bioartificial liver with recombinant HepG2 cells using pigs with ischemic liver failure.[J].2001,10(4).
[16]Sarkis R,Honiger J,Delelo R,etc.Transplanted cryopreserved encapsulated porcine hepatocytes are as effective as fresh hepatocytes in preventing death from acute liver failure in rats.[J].2000,70(1).
[17].Primary Porcine Hepatocytes with Portal Vein Serum Cultured on Microcarriers or in Spheroidal Aggregates[J].2000,(3).
[18]Ding Y,Chen Z,Zhang H.Morphology, viability and functions of suckling pig hepatocytes cultured in serum-free medium at high density.[J].2002,19(3).
[19]Baust JG,Vogel MJ,Van-Buskirk R,etc.A molecular basis of cryopreservation failure and its modulation to improve cell survival.[J].2001,10(7).
[20]André Guillouzo,Laure Rialland,Alain Fautrel,etc.Survival and function of isolated hepatocytes after cryopreservation[J].1999,121(1).
[21]Theodore M. Khalili,Antonio Navarro,Paul Ting,etc.Bioartificial Liver Treatment Prolongs Survival and Lowers Intracranial Pressure in Pigs with Fulminant Hepatic Failure[J].2001,25(7).
[22]K, Funatsu,H, Ijima,K, Nakazawa,etc.Hybrid artificial liver using hepatocyte organoid culture.[J].2001,25(3).
[23]E S, Tzanakakis,D J, Hess,T D, Sielaff,etc.Extracorporeal tissue engineered liver-assist devices.[J].2000,2.
[24]Hubel A,Darr TB.Postthaw viability of precultured hepatocytes.[J].2001,42(1).
[25]A Bader,T Hansen,G Kirchner,etc.Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions[J].2000,129(2).
[26]E, Morsiani,M, Brogli,D, Galavotti,etc.Long-term expression of highly differentiated functions by isolated porcine hepatocytes perfused in a radial-flow bioreactor.[J].2001,25(9).
[27]Scoletta P,Morsiani E,Gorini P,etc.Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients.[J].2002,25(3).
[28]GAO Yi,XU Xiao-ping,HU Huan-zhang,etc.Cultivation of human liver cell lines with microcarriers acting as biological materials of bioartificial liver[J].1999,(3).
[29]Nelson LJ,Newsome PN,Tsiaoussis J,etc.Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems.[J].2001,7(1).
[30]Clement B,Desille M,Campion JP,etc.Follow-up by one- and two-dimensional NMR of plasma from pigs with ischemia-induced acute liver failure treated with a bioartificial liver.[J].2002,15(6).
[31]Sarkis R,Becquemont L,Balladur P,etc.Semiautomatic macroencapsulation of fresh or cryopreserved porcine hepatocytes maintain their ability for treatment of acute liver failure.[J].2001,10(7).
[32]Diener B,Ringel M,Swales N,etc.Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction.[J].2000,32(1).